BIONIME CORPORATION Company Profile

Company Overview:

BIONIME CORPORATION  is a Taiwan-based company engaged in the manufacture and distribution of blood glucose monitoring systems. The company also has operations in Switzerland, the US, China, Australia and British Virgin Islands.

The company offers blood glucose monitoring systems such as GM100, GM300, GM260, GM550, GM720, GM700, GM700S and GM720 series.

GM100 slim series is intended for vitro diagnostic use. The device is calibrated for test with capillary whole blood samples from the fingertip, palm or forearm. GM300 and GM260 series are used for testing patient blood glucose level.

GM550 series enables people to read their test results even in the dark. GM700, GM720 and GM700S series has the feature of preventing oxygen interference. In addition, the company also has Rightest Diabetes Management System (DMS) software.

Geographically, the company classifies its operations into four segments, namely United States, Switzerland, Chinese and Other countries. In FY2016, United States segment accounted for 10.6% of the company's total revenues, followed by Switzerland with 18.2%; Chinese with 24.1%; and Other countries with 47.1%.

BIONIME's subsidiaries include the following: BIONIME GmbH, BIONIME USA, BIONIME (ShenZhen) and Bionime Incorporated (B.V.I.).

Scope of the Report

• About the Company - Historical Details, Current Ownership Structure and basic overview of BIONIME CORPORATION in terms of revenue, net income, and operating income.
• Financials - Details about BIONIME CORPORATION listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
• Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
• Company SWOT Analysis - Outlines BIONIME CORPORATION’s strengths, weaknesses, and opportunities and threats facing the company.
• Recent Developments - Showcases BIONIME CORPORATION’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
• Strategic Evaluation - Provides an overview of BIONIME CORPORATION’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
• Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

• What domain does BIONIME CORPORATION operate and what are key points about it?
• What is the product / service portfolio of BIONIME CORPORATION?
• How has BIONIME CORPORATION performed financially from the 2013?
• How does BIONIME CORPORATION rank among its peers in terms of revenue and market share?
• What are BIONIME CORPORATION strengths and weaknesses and what opportunities and threats does it face?
• What are BIONIME CORPORATION’s main growth strategies and how successful has the company been at implementing them?
• What is the in-house technical capability of BIONIME CORPORATION? Where does it procure / outsource it?

Reasons to buy

• Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
• Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
• 12 hour delivery time fulfilling your urgent requests as per your requirement
• On-demand customization options that can completely cater to your needs by focusing the report onto given specifics